($VRTX): Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. For the fiscal year ended 31 December 2012, Vertex Pharmaceuticals Incorporated revenues increased 8% to $1.53B. Net loss applicable to common stockholders totaled $107M vs. income of $29.3M. The stock has moved out of a base that began in January. A move over 49.83 and we will look at the March 49 calls.